News Breaks |
|
|
| September 21, 2012 |
| 07:31 EDT |  | MYL, PFE | Mylan launches generic version of Pfizer's Antivert
Mylan (MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Meclizine Hydrochloride Tablets USP, 12.5 mg, 25 mg and 50 mg. This product is the generic version of Pfizer's (PFE) Antivert, which is indicated for the management of nausea and vomiting, and dizziness associated with motion sickness. Antivert Tablets, 12.5 mg, 25 mg and 50 mg, had U.S. sales of approximately $53.5M for the 12 months ending June 30, according to IMS Health. Mylan is shipping this product immediately, it said. |
|
|
News For MYL;PFE From The Last 14 Days Check below for free stories on MYL;PFE the last two weeks. |
|
|
| May 21, 2013 |
| 07:35 EDT | | MYL | Mylan: Appellate Court rules in favor of company in patent infringement case
 Subscribe for More Information |
|
| 07:16 EDT |  | PFE | Pfizer management to meet with Leerink
Subscribe for More Information |
|
| May 20, 2013 |
| 17:04 EDT | | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information |
|
| 11:27 EDT | | MYL | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| May 17, 2013 |
| 14:48 EDT |  | MYL | Actavis may bid for Warner Chilcott to ward off takeover, Reuters says
Subscribe for More Information |
|
| 13:56 EDT | | MYL | Actavis may purchase Warner Chilcott as takeover defense, Reuters reports
Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. |
|
| 07:31 EDT | | MYL | Mylan launches generic Tricor tablets
Subscribe for More Information |
|
| May 16, 2013 |
| 08:55 EDT | | PFE | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT | | MYL | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 17:36 EDT | | MYL | Paulson gives quarterly update on stakes
Subscribe for More Information |
| |
| 11:42 EDT | | MYL | Mylan launches generic Zomig tablets
Subscribe for More Information |
|
| 07:03 EDT |  | MYL | Mylan highly unlikely to acquire Actavis, says Barclays
Subscribe for More Information |
|
| May 14, 2013 |
| 13:55 EDT | | MYL | Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says
Subscribe for More Information |
|
| 13:22 EDT | | MYL | Actavis turned down $15B takeover bid from Mylan, Bloomberg reports
Subscribe for More Information |
|
| May 10, 2013 |
| 16:29 EDT |  | PFE | On The Fly: Closing Wrap
Subscribe for More Information |
|
| 12:31 EDT | | PFE | On The Fly: Midday Wrap
Subscribe for More Information |
|
| 11:48 EDT | | PFE | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 10:00 EDT |  | MYL | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. |
|
| 09:21 EDT | | PFE | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:08 EDT | | PFE | Pain Therapeutics discloses Pfizer reassessing continued Remoxy partnership
Pain Therapeutics (PTIE) disclosed a letter its CEO was sent from partner Pfizer (PFE) in which the drug maker said it is reassessing its endorsement of the Remoxy program "given the years of delay, additional cost incurred to bring the program to this point and development work left in the program." Pfizer said it will be reaching out to Pain Therapeutics "shortly" to have a confidential discussion about the terms of the companies' contractual agreement over the pain drug. Pfizer that it appears there is a regulatory pathway forward for Remoxy, but that the company does not expect to respond to submit a Complete Response letter for Remoxy to the FDA before mid-2015. Pfizer added in its letter to Pain Therapeutics "no final decision has been made at this time" on how it will proceed with the Remoxy development program. Shares of Pain Therapeutics fell 47% to $2.81 in pre-market trading following the disclosure of the correspondence. |
| |
|
|
|
|
